Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 22, 2021 08:00 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics Regains Compliance with Nasdaq Continued Listing Requirement

NEWTOWN, Pa., June 22, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products for patients...
June 17, 2021 08:00 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics Announces the Peer-Reviewed Publication of Preclinical Data Demonstrating the Synergistic Anti-Cancer Activity of Rigosertib Combined with Immune Checkpoint Blockade

Rigosertib synergistically combined with immune checkpoint blockade (ICB) to improve tumor growth inhibition and survival in a murine melanoma model that did not respond to ICB alone Rigosertib’s...
June 10, 2021 08:00 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics Announces Participation in A.G.P.’s Upcoming Virtual Summer Healthcare Symposium

NEWTOWN, Pa., June 10, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
June 03, 2021 08:00 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics Announces Upcoming Presentation at 2021 BIO Digital

NEWTOWN, Pa., June 03, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
June 01, 2021 08:00 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics Announces the Appointment of Mark Gelder, M.D., as Chief Medical Officer

NEWTOWN, Pa., June 01, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
May 21, 2021 08:00 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics Announces the Initial Dosing of the First Patient in the U.S. Phase 1 Clinical Trial of ON 123300

NEWTOWN, Pa., May 21, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for...
May 20, 2021 08:32 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics Announces Reverse Stock Split and Decrease in Authorized Shares

NEWTOWN, Pa., May 20, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq: ONTX) (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and...
May 17, 2021 16:05 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

Conference call and live webcast at 4:30 p.m. ET today NEWTOWN, Pa., May 17, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical...
May 10, 2021 08:00 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics to Provide Corporate Update and Announce First Quarter 2021 Financial Results on May 17, 2021

NEWTOWN, Pa., May 10, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for...
April 22, 2021 08:00 ET | Source: Onconova Therapeutics, Inc.

Onconova Announces First Patient Dosed in Investigator-Initiated Phase 2 Study of Rigosertib in Recessive Dystrophic Epidermolysis Bullosa-Associated Squamous Cell Carcinoma

NEWTOWN, Pa., April 22, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right